[Shareholding] Majority owned by Samsung C&T (43.06%) and Samsung Electronics (31.22%), total same-person group 74.39%. Treasury shares: 51,433 (0.11%). Other shareholders 25.61%.
[Affiliate Change] HUMAN GENOME SCIENCES, INC (USA, 100% subsidiary) added in March 2026 via equity acquisition. Likely to strengthen R&D and manufacturing capabilities in the US market.
[Board & Management] CEO John Rim serves as Chairman of the Board and Management Committee. 7 directors (3 inside, 4 outside). Committees (Audit, Compensation, ESG etc.) functioning normally. Electronic voting system adopted (voting ratio 1.89%).
[Internal Transactions] Mainly CMO/CRO transactions with Samsung Bioepis (sales of 277.4B KRW). Minor service purchases from public-interest foundations (e.g., Samsung Medical Foundation 3.65B KRW). No significant issues.
[AI Summary]This is a routine annual conglomerate disclosure confirming Samsung Biologics’ stable financial health and governance. The new affiliate (HUMAN GENOME SCIENCES) is a positive long-term move but has limited short-term price impact. For investors, it reaffirms the company’s steady fundamentals.
KOSPI Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]